This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07519135 |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Pfizer |
| Enrollment | 26 participants |
| Design | Interventional, Na, Parallel, Masking: None |
| Conditions | Healthy |
| Interventions | PF-08653944 |
| Start | Apr 15, 2026 |
| Primary completion | Jul 9, 2027 |
| Study completion | Jul 9, 2027 |
| Results posted | Not yet |
| Registry last updated | Apr 23, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is being done to learn more about an investigational medicine called PF-08653944. The goal is to understand how the body handles the medicine and to check its safety after a single dose.
The study includes adults with normal liver function and adults who have mild, moderate, or severe liver problems. By comparing these groups, researchers want to understand whether liver function changes how the medicine behaves in the body.
People who join the study will receive one injection of the study medicine. They will stay at the study clinic for a short time and return for follow-up visits so doctors can do blood tests, physical exams, and safety checks.
This study is not expected to provide direct medical benefit to participants. The information collected will help researchers develop future treatments and understand how this medicine may be used safely in people with liver disease.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Pharmacokinetics (PK): Maximum observed plasma concentration (Cmax) of PF-08653944 | Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention. |
| PK: Area under the plasma concentration (AUC) of PF-08653944 | Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention. |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of Berobenatide
- A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood (Phase 1 NCT07400679)
- A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the (Phase 1 NCT07508241)
More from Pfizer
- VESPER-OSA 2: sleep apnea without airway pressure therapy (Phase 3 NCT07881757)
- Once-monthly berobenatide in Chinese adults (Phase 3) (Phase 3 NCT07874633)
- VESPER-JW: once-weekly berobenatide in Japan (Phase 3 NCT07794761)
- VESPER-SWITCH: monthly berobenatide for weight maintenance (Phase 3 NCT07845500)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.